N/A N=203 Optimization and Refinement of Technique in In-Office Sinus Dilation 2
Sinusitis
Primary: Mean Intra-patient Change in SNOT-20 Score — -1.16 Scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Differential Effects of Zolpidem Versus Ramelteon in Burned Children
Sleep · Burns
Primary: Polysomnography Data — 373; 346 minutes
N/A N=6 Team Based Initiative Support
Traumatic Brain Injury
Primary: Number of Participants Who Reported 5 Themes — 6; 6; 6; 6 participants
Phase 3 N=1,010 Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
HIV · Sexually Transmitted Diseases · HIV Infections
Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners
N/A N=300 Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes
Diabetes
Primary: General Trust in Physicians Scale (GTIPS) — 39.0; 39.5 units on a scale — p=0.648
Phase 3 N=1,281 Rapid HIV Testing and Counseling in Drug Abuse Treatment
Substance-Related Disorders
Primary: Self-Report Receipt of HIV Test Results — 78; 338; 347 participants — p=<0.001
N/A N=17 Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study
Menorrhagia
Primary: To Assess the Efficacy of Oral TA and COCP in Adolescents With Menorrhagia. — 536.4; 430.6; 15.6; 16.75 Scores on a scale — p=0.01
Phase 2 N=14 Artificial Pancreas Control System in an Inpatient Setting
Type I Diabetes Mellitus
Primary: Mean Percent of Time in Target Blood Glucose Range — 62.4 percentage of time
Phase 3 N=285 Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events — 77; 18; 92; 90 participants
N/A N=58 Post Marketing Observational Study of Reformulated BeneFIX
Hemophilia B
Primary: Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Safety Amendment — 1; 1; 0; 1 participants
Phase 4 N=50 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24 — 82.0 percentage of participants
Phase 2 N=28 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Alzheimer's Disease · Frontotemporal Dementia
Primary: Qualitative Amyloid Image Assessment — 2; 1; 8; 4 participants
Phase 4 N=194 A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Digit Span Test Total Score at Week 12 — 11.7; 13.7; 1; 0.5 Scores on a scale — p=0.0387
Phase 3 N=342 A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
Chronic Obstructive Pulmonary Disease
Primary: Clinical Response in the Clinical Populations — 86.71; 86.26 percentage of participants
Phase 3 N=165 Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
Migraine Disorders · Heart Disease · Cerebrovascular Accident
Primary: Percentage of Participants With Pain Freedom at 2 Hours Post-dose (Period 1, Migraine Attack 1) — 25.0; 18.9 Percentage of participants — p=0.329